CAMBRIDGE, MASS. – [August 16, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of industry leader, Jeb Keiper, as an independent member of its Board of Directors. Mr. Keiper joins founder Michael Mendelsohn, M.D., Ken Novack, Ed Mascioli, M.D. and chief executive officer Daniel Bloomfield, M.D. as members, along with board observers, Stephen Hitchcock, Ph.D. and Keith Gottesdiener, M.D.
“We are fortunate to have amassed a tremendous breadth and depth of expertise in drug discovery, development, and business amongst our board members, observers and advisors, which positions Cardurion well to deliver on our vision of becoming the world’s leading cardiovascular drug company,” said Daniel Bloomfield, M.D., chief executive officer at Cardurion Pharmaceuticals. “We are thrilled to have Jeb share his expertise and leadership skills as Cardurion takes on the challenges and opportunities of the company’s next critical phase of growth.”
Jeb Keiper has 20 years of experience in the pharmaceutical and biotech industries with extensive expertise in financing and business development transactions. Mr. Keiper currently serves as chief financial officer and chief business officer at Nimbus Therapeutics, LLC, where he has overseen over $700m of capital inflows via a variety of financing and partnering transactions since joining in 2014. Prior to joining Nimbus, Mr. Keiper was vice president of business development at GSK Oncology and spent a decade at GSK in various business development leadership roles. Mr. Keiper led the oncology portion of the GSK-Novartis 3-business swap for $16b announced in April 2014. Earlier in his career, Mr. Keiper was a consultant at McKinsey and Company and worked in business development at TransForm Pharmaceuticals. Mr. Keiper began his career at Pfizer R&D as a bench chemist. He received four degrees from MIT: one in Chemistry, two in Chemical Engineering, and an MBA from MIT Sloan.
“Cardurion has built an exceptional company focused on addressing multiple pathways in the cardiomyocyte,” said Mr. Keiper. “I look forward to working with the leadership team and fellow board members as Cardurion continues to build a novel portfolio of clinical and preclinical programs for patients with cardiovascular disease.”
For additional information on Cardurion Pharmaceuticals’ board and leadership team, please visit the company’s website: http://www.cardurion.com.
About Cardurion Pharmaceuticals
Cardurion is a biotechnology company with both clinical and preclinical programs focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by two physician-scientists with extensive experience in cardiovascular science, medicine and drug development, Cardurion’s unique programs and strongly collaborative environment enable the company to deliver promising treatments that target major unmet needs. Cardurion has facilities in Cambridge, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at http://www.cardurion.com.
Cardurion Pharmaceuticals’ Forward Looking Statements
This press release contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Any statements contained herein that do not describe historical facts, are forward-looking statements that are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to: the costs and uncertainties associated with our research efforts and other discovery activities; the inherent uncertainties associated with the conduct, timing and results of preclinical and clinical studies of our product candidates; and the adequacy of our capital resources and availability of additional funding. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise any of such statements to reflect events or circumstances occurring after this press release. We caution readers not to place undue reliance on the forward-looking statements contained in this press release.
The safety and efficacy of the agent discussed herein are under investigation and have not been established. There is no guarantee that the agent will receive regulatory approval and become commercially available for the uses being investigated. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.